Article Text
Statistics from Altmetric.com
Q In pregnant women at risk, is prophylactic use of antiplatelet agents (such as aspirin and dipyridamole) effective for preventing or delaying the development of pre-eclampsia as well as other related maternal and child outcomes?
Clinical impact ratings FP/GP/Obstetrics ★★★★★★☆ Obstetrics ★★★★★★☆
METHODS
Data sources:
the Cochrane Pregnancy and Childbirth Group trials register (September 2003), the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 2, 2003), EMBASE/Excerpta Medica (1994–2003), and congress proceedings of the International and European Societies for the Study of Hypertension in Pregnancy (up to 2002).
Study selection and assessment:
randomised controlled trials (RCTs) that compared any antiplatelet agent (such as low dose aspirin or dipyridamole) with a control condition comprising placebo or no antiplatelet agent in pregnant women considered to be at risk of developing pre-eclampsia. Exclusion criteria included comparisons of 1 antiplatelet agent with another, and of antiplatelets with other interventions. Study quality was assessed …
Footnotes
-
For correspondence: Dr L Duley, Institute of Health Sciences, Oxford, UK. Lelia.duleyndm.ox.ac.uk
-
Sources of funding: not stated.
Linked Articles
- Glossary